Sila Realty Trust Reports Strong 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Source: Newsfilter
- Net Income Performance: For Q4 2025, Sila reported a net income of $5.0 million, or $0.09 per diluted share, down from $11.1 million in Q4 2024, reflecting challenges in market competition while underscoring its ongoing investment strategy in healthcare real estate.
- Cash NOI Growth: The cash net operating income for Q4 2025 reached $44.0 million, a 7.3% increase year-over-year, primarily driven by newly acquired healthcare properties and same-store cash NOI growth, indicating effective asset management and stable market demand.
- Annual Dividend Policy: The company declared a cash dividend of $1.60 per share for 2025, with a quarterly dividend of $0.40, demonstrating a commitment to shareholder returns and reflecting its stable cash flow and profitability.
- Portfolio Expansion: As of December 31, 2025, Sila owned 140 properties with approximately 5.3 million rentable square feet and a leasing rate of 98.7%, indicating a strong position in the healthcare real estate market and significant growth potential moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SILA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SILA
Wall Street analysts forecast SILA stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 30.250
Low
28.00
Averages
28.00
High
28.00
Current: 30.250
Low
28.00
Averages
28.00
High
28.00
About SILA
Sila Realty Trust, Inc. is a real estate investment trust. The Company is primarily focused on investing in high-quality healthcare facilities across the continuum of care, which the Company believes typically generates predictable, durable and growing income streams. Its portfolio comprises tenants in geographically diverse facilities, which are positioned to capitalize on the dynamic delivery of healthcare to patients. The Company owns approximately 136 real estate properties, and two undeveloped land parcels located in 66 markets across the United States. Its portfolio includes Akron Healthcare Facility, Alexandria Healthcare Facility, Allen Healthcare Facility, Appleton Healthcare Facility, Augusta Healthcare Facility, Beaumont Healthcare Facility, Bellevue Healthcare Facility, Carrollton Healthcare Facility, Cincinnati Healthcare Facility, Yukon Healthcare Facility, El Segundo Healthcare Facility, Dallas Healthcare Facility, Pleasant Hills Healthcare Facility, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE:SILA) for its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, raising concerns about potential shareholder rights violations and encouraging shareholders to explore their options.
- Acquisition Terms: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is being sold to Chiesi Group for $27.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration to ensure fair compensation for shareholders.
- Transaction Options: Thermon Group Holdings, Inc. (NYSE:THR) is proposed to be sold to CECO Environmental Corp., offering shareholders a choice between cash and stock combinations or $63.89 per share in cash, with Halper Sadeh LLC advocating for better terms on behalf of shareholders.
- Legal Support: Lisata Therapeutics, Inc. (NASDAQ:LSTA) is selling to Kuva Labs, Inc. for $4.00 per share, and Halper Sadeh LLC provides no-cost legal consultations to help shareholders understand their rights and options, ensuring their legal interests are protected.
See More
Investigation Alerts for Multiple Company Mergers
- KalVista Merger Investigation: KalVista Pharmaceuticals is set to be acquired by Chiesi Group for $27.00 per share, implying a total value of approximately $1.9 billion, with investigations focusing on whether the board breached fiduciary duties by failing to conduct a fair process.
- Thermon Acquisition Review: Thermon Group Holdings will be acquired by CECO Environmental in a deal valued at around $2.2 billion, allowing shareholders to choose between cash and stock, with investigations into potential breaches of fiduciary duties by the board regarding fair treatment of shareholders.
- Sila Realty Acquisition Inquiry: Sila Realty Trust is to be acquired by Blue Owl Capital for $30.38 per share, totaling approximately $2.4 billion, with investigations examining whether the board failed to ensure a fair process and fair value for shareholders.
- Lisata Therapeutics Merger Scrutiny: Lisata Therapeutics will be acquired by Kuva Labs for $4.00 per share plus contingent value rights, with investigations into whether the board breached fiduciary duties by not ensuring fair value in the transaction for shareholders.
See More
Sila Realty Trust Declares Quarterly Dividend of $0.40
- Quarterly Dividend Announcement: Sila Realty Trust declares a quarterly dividend of $0.40 per share, consistent with previous distributions, indicating the company's stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Dividend Yield: The forward yield of 5.23% makes this dividend attractive in the current market environment, potentially drawing in income-seeking investors and enhancing the company's competitive position within the Real Estate Investment Trust (REIT) sector.
- Financial Performance: Sila Realty Trust reports a GAAP EPS of $0.22 and revenue of $52.66 million, reflecting the company's ongoing growth potential in the high-yield healthcare real estate sector, despite facing AFFO headwinds, growth drivers are gradually aligning.
- Market Dynamics: The recent acquisition activities of Sila Realty Trust highlight that many REITs are still trading at a discount, potentially offering investors an opportunity to enter high-yield assets, further driving market interest in the company.
See More
Sila Realty Trust Q1 Financial Highlights
- Financial Performance: Sila Realty Trust reported Q1 AFFO of $0.61 and GAAP EPS of $0.22, with revenue reaching $52.66 million, indicating stable growth in the healthcare REIT sector.
- Cash Distributions: The company declared and paid cash distributions of $0.40 per share for the quarter, reflecting strong cash flow and commitment to shareholder returns, thereby enhancing investor confidence.
- Asset Acquisition: On January 15, 2026, the company acquired an inpatient rehabilitation facility in Oklahoma City for $43.3 million, marking a strategic expansion in its healthcare facility portfolio.
- Asset Sales: The company sold four healthcare facilities for a total of $25.1 million, generating net proceeds of $24.8 million after transaction costs, demonstrating proactive asset optimization and capital efficiency efforts.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE: SILA) for its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, raising concerns about potential shareholder rights violations and urging shareholders to explore their options.
- Esperion Transaction: Esperion Therapeutics, Inc. (NASDAQ: ESPR) is being sold to funds managed by ARCHIMED for $3.16 per share in cash, along with rights to contingent milestone payments, which may affect shareholder returns, prompting shareholders to understand their legal rights.
- Merger Details: Corebridge Financial, Inc. (NYSE: CRBG) is merging with Equitable Holdings, Inc., with Corebridge shareholders expected to own approximately 51% of the combined entity, highlighting the need for shareholders to assess the implications of the merger terms on their interests.
- Legal Advocacy: Halper Sadeh LLC represents investors globally, seeking increased consideration and additional disclosures for affected shareholders, emphasizing the firm's commitment to protecting shareholder interests and pursuing corporate accountability.
See More
Investigations into Multiple Biotech Company Mergers
- Esperion Acquisition Investigation: Esperion Therapeutics is set to be acquired by ARCHIMED for $3.16 per share in cash, with potential contingent milestone payments of up to $100 million, raising concerns about whether the board breached fiduciary duties by failing to ensure fair pricing for shareholders.
- Sila Realty Acquisition Scrutiny: Sila Realty Trust will be acquired by Blue Owl Capital for $30.38 per share in an all-cash deal valued at approximately $2.4 billion, with investigations questioning whether the board adequately protected shareholder interests during the transaction process, potentially affecting fair value.
- Lisata Therapeutics Merger Investigation: Lisata Therapeutics is being acquired by Kuva Labs for $4.00 per share in cash, along with two non-tradeable rights, prompting investigations into whether the board conducted a fair process, which could impact shareholder benefits.
- SkyWater Technology Acquisition Review: SkyWater is to be acquired by IonQ for $35.00 per share in a cash-and-stock deal valued at around $1.8 billion, with investigations focusing on whether the board fulfilled its fiduciary duties, particularly as the deal price is below the company's 52-week high of $36.27.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE:SILA) for its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, raising concerns about potential shareholder rights violations and encouraging shareholders to explore their options.
- Acquisition Terms: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) is being sold to Chiesi Group for $27.00 per share in cash, with Halper Sadeh LLC potentially seeking increased consideration to ensure fair compensation for shareholders.
- Transaction Options: Thermon Group Holdings, Inc. (NYSE:THR) is proposed to be sold to CECO Environmental Corp., offering shareholders a choice between cash and stock combinations or $63.89 per share in cash, with Halper Sadeh LLC advocating for better terms on behalf of shareholders.
- Legal Support: Lisata Therapeutics, Inc. (NASDAQ:LSTA) is selling to Kuva Labs, Inc. for $4.00 per share, and Halper Sadeh LLC provides no-cost legal consultations to help shareholders understand their rights and options, ensuring their legal interests are protected.
See More
Investigation Alerts for Multiple Company Mergers
- KalVista Merger Investigation: KalVista Pharmaceuticals is set to be acquired by Chiesi Group for $27.00 per share, implying a total value of approximately $1.9 billion, with investigations focusing on whether the board breached fiduciary duties by failing to conduct a fair process.
- Thermon Acquisition Review: Thermon Group Holdings will be acquired by CECO Environmental in a deal valued at around $2.2 billion, allowing shareholders to choose between cash and stock, with investigations into potential breaches of fiduciary duties by the board regarding fair treatment of shareholders.
- Sila Realty Acquisition Inquiry: Sila Realty Trust is to be acquired by Blue Owl Capital for $30.38 per share, totaling approximately $2.4 billion, with investigations examining whether the board failed to ensure a fair process and fair value for shareholders.
- Lisata Therapeutics Merger Scrutiny: Lisata Therapeutics will be acquired by Kuva Labs for $4.00 per share plus contingent value rights, with investigations into whether the board breached fiduciary duties by not ensuring fair value in the transaction for shareholders.
See More
Sila Realty Trust Declares Quarterly Dividend of $0.40
- Quarterly Dividend Announcement: Sila Realty Trust declares a quarterly dividend of $0.40 per share, consistent with previous distributions, indicating the company's stable cash flow and shareholder return strategy, which is expected to bolster investor confidence.
- Dividend Yield: The forward yield of 5.23% makes this dividend attractive in the current market environment, potentially drawing in income-seeking investors and enhancing the company's competitive position within the Real Estate Investment Trust (REIT) sector.
- Financial Performance: Sila Realty Trust reports a GAAP EPS of $0.22 and revenue of $52.66 million, reflecting the company's ongoing growth potential in the high-yield healthcare real estate sector, despite facing AFFO headwinds, growth drivers are gradually aligning.
- Market Dynamics: The recent acquisition activities of Sila Realty Trust highlight that many REITs are still trading at a discount, potentially offering investors an opportunity to enter high-yield assets, further driving market interest in the company.
See More
Sila Realty Trust Q1 Financial Highlights
- Financial Performance: Sila Realty Trust reported Q1 AFFO of $0.61 and GAAP EPS of $0.22, with revenue reaching $52.66 million, indicating stable growth in the healthcare REIT sector.
- Cash Distributions: The company declared and paid cash distributions of $0.40 per share for the quarter, reflecting strong cash flow and commitment to shareholder returns, thereby enhancing investor confidence.
- Asset Acquisition: On January 15, 2026, the company acquired an inpatient rehabilitation facility in Oklahoma City for $43.3 million, marking a strategic expansion in its healthcare facility portfolio.
- Asset Sales: The company sold four healthcare facilities for a total of $25.1 million, generating net proceeds of $24.8 million after transaction costs, demonstrating proactive asset optimization and capital efficiency efforts.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. (NYSE: SILA) for its sale to Blue Owl Real Estate Capital LLC at $30.38 per share, raising concerns about potential shareholder rights violations and urging shareholders to explore their options.
- Esperion Transaction: Esperion Therapeutics, Inc. (NASDAQ: ESPR) is being sold to funds managed by ARCHIMED for $3.16 per share in cash, along with rights to contingent milestone payments, which may affect shareholder returns, prompting shareholders to understand their legal rights.
- Merger Details: Corebridge Financial, Inc. (NYSE: CRBG) is merging with Equitable Holdings, Inc., with Corebridge shareholders expected to own approximately 51% of the combined entity, highlighting the need for shareholders to assess the implications of the merger terms on their interests.
- Legal Advocacy: Halper Sadeh LLC represents investors globally, seeking increased consideration and additional disclosures for affected shareholders, emphasizing the firm's commitment to protecting shareholder interests and pursuing corporate accountability.
See More
Investigations into Multiple Biotech Company Mergers
- Esperion Acquisition Investigation: Esperion Therapeutics is set to be acquired by ARCHIMED for $3.16 per share in cash, with potential contingent milestone payments of up to $100 million, raising concerns about whether the board breached fiduciary duties by failing to ensure fair pricing for shareholders.
- Sila Realty Acquisition Scrutiny: Sila Realty Trust will be acquired by Blue Owl Capital for $30.38 per share in an all-cash deal valued at approximately $2.4 billion, with investigations questioning whether the board adequately protected shareholder interests during the transaction process, potentially affecting fair value.
- Lisata Therapeutics Merger Investigation: Lisata Therapeutics is being acquired by Kuva Labs for $4.00 per share in cash, along with two non-tradeable rights, prompting investigations into whether the board conducted a fair process, which could impact shareholder benefits.
- SkyWater Technology Acquisition Review: SkyWater is to be acquired by IonQ for $35.00 per share in a cash-and-stock deal valued at around $1.8 billion, with investigations focusing on whether the board fulfilled its fiduciary duties, particularly as the deal price is below the company's 52-week high of $36.27.
See More
